This week in therapeutics




Licensing status

Publication and contact information

Endocrine/metabolic disease


Phosphoinositide 3-kinase (PI3K); phosphatase and tensin homolog deleted on chromosome 10 (PTEN; MMAC1; TEP1); protein kinase B (PKB; PKBA; AKT; AKT1)

Mouse studies suggest AS101 could help prevent cyclophosphamide-induced depletion of ovarian follicles, which leads to infertility. In female mice, cyclophosphamide enhanced Pi3k-Pten-Akt signaling and decreased primordial ovarian follicles compared with vehicle. In female mice, the Pi3k-Pten-Akt pathway inhibitor AS101 decreased cyclophosphamide-induced follicle loss and rescued fertility compared with saline. Next steps include evaluating the ability of AS101 to protect ovarian follicles in nonhuman primates.

BioMAS Ltd.' s AS101 is in Phase II testing to prevent chemotherapy-associated hematological toxicity.

Cyclophosphamide is a generic chemotherapeutic.

SciBX 6(23); doi:10.1038/scibx.2013.578
Published online June 13, 2013

Patented; available for licensing from BioMAS Ltd.

Contact: Ayelet Dilion-Mashiah, BioMAS Ltd., Jerusalem, Israel

Kalich-Philosoph, L. et al. Sci. Trans. Med.; published online May 15, 2013;
Contact: Dror Meirow, Tel Aviv University, Tel Aviv, Israel